|
× |
 |
DEXTROSE MONOHYDRATE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
DOCUSATE SODIUM Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
ENTRESTO (sacubitril; valsartan) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
SHELLAC Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
CELLULOSE, MICROCRYSTALLINE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
EGATEN (triclabendazole) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
CALCIUM SULFATE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
D&C RED NO. 28 Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
ERLEADA (apalutamide) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
EMFLAZA (deflazacort) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
|